Tweet
Produced on 4 January 2023, 12:00
The next update of this bulletin will be published on 18 January 2023 and biweekly thereafter.
Surveillance summary
A total of 25,736 cases of mpox (formerly named monkeypox) have been identified through IHR mechanisms, official public sources and TESSy up to 3 January 2023, 14:00, from 45 countries and areas throughout the European Region. Over the past 4 weeks, 185 cases of mpox have been identified from 15 countries and areas.
Case-based data were reported for 25,656 cases from 41 countries and areas to ECDC and the WHO Regional Office for Europe through The European Surveillance System (TESSy), up to 3 January 2023, 10:00.
Of the 25,656 cases reported in TESSy, 25,471 were laboratory confirmed. Furthermore, where sequencing was available, 488 were confirmed to belong to Clade II, formerly known as the West African clade. The earliest known case has a specimen date of 07 March 2022 and was identified through retrospective testing of a residual sample. The earliest date of symptom onset was reported as 17 April 2022.
The majority of cases were between 31 and 40 years-old (10,112/25,626 - 39%) and male (25,161/25,595 - 98%). Of the 11,026 male cases with known sexual orientation, 96% self-identified as men who have sex with men. Among cases with known HIV status, 38% (3,927/10,366) were HIV-positive. The majority of cases presented with a rash (15,199/15,913 - 96%) and systemic symptoms such as fever, fatigue, muscle pain, chills, or headache (10,766/15,913 - 68%). There were 773 cases hospitalised (6%), of which 264 cases required clinical care. Seven cases were admitted to ICU, and five cases of mpox were reported to have died.
To date, WHO and ECDC have been informed of five cases of occupational exposure. In four cases of occupational exposure, health workers were wearing recommended personal protective equipment but were exposed to body fluid while collecting samples. The fifth case was not wearing personal protective equipment. The WHO interim guidance on clinical management and infection prevention and control for mpox remains valid and is available at https://apps.who.int/iris/handle/10665/355798.
INTRODUCTIONThis report provides an overview of the total number of cases of mpox (formerly named monkeypox) identified by ECDC and the WHO Regional Office for Europe through IHR mechanisms and official public sources and case-based data through The European Surveillance System (TESSy) up to 3 January 2023. ...
The next update of this bulletin will be published on 18 January 2023 and biweekly thereafter.
Surveillance summary
A total of 25,736 cases of mpox (formerly named monkeypox) have been identified through IHR mechanisms, official public sources and TESSy up to 3 January 2023, 14:00, from 45 countries and areas throughout the European Region. Over the past 4 weeks, 185 cases of mpox have been identified from 15 countries and areas.
Case-based data were reported for 25,656 cases from 41 countries and areas to ECDC and the WHO Regional Office for Europe through The European Surveillance System (TESSy), up to 3 January 2023, 10:00.
Of the 25,656 cases reported in TESSy, 25,471 were laboratory confirmed. Furthermore, where sequencing was available, 488 were confirmed to belong to Clade II, formerly known as the West African clade. The earliest known case has a specimen date of 07 March 2022 and was identified through retrospective testing of a residual sample. The earliest date of symptom onset was reported as 17 April 2022.
The majority of cases were between 31 and 40 years-old (10,112/25,626 - 39%) and male (25,161/25,595 - 98%). Of the 11,026 male cases with known sexual orientation, 96% self-identified as men who have sex with men. Among cases with known HIV status, 38% (3,927/10,366) were HIV-positive. The majority of cases presented with a rash (15,199/15,913 - 96%) and systemic symptoms such as fever, fatigue, muscle pain, chills, or headache (10,766/15,913 - 68%). There were 773 cases hospitalised (6%), of which 264 cases required clinical care. Seven cases were admitted to ICU, and five cases of mpox were reported to have died.
To date, WHO and ECDC have been informed of five cases of occupational exposure. In four cases of occupational exposure, health workers were wearing recommended personal protective equipment but were exposed to body fluid while collecting samples. The fifth case was not wearing personal protective equipment. The WHO interim guidance on clinical management and infection prevention and control for mpox remains valid and is available at https://apps.who.int/iris/handle/10665/355798.
INTRODUCTIONThis report provides an overview of the total number of cases of mpox (formerly named monkeypox) identified by ECDC and the WHO Regional Office for Europe through IHR mechanisms and official public sources and case-based data through The European Surveillance System (TESSy) up to 3 January 2023. ...